All In Biotech

Drug Trial Radar · NCT03839524

A Trial Evaluating TG4050 in Ovarian Carcinoma.

A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.

Last checked: Nov 19, 2026Latest source record: Nov 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

64

Actual

Start

Dec 9, 2019

Primary completion

Oct 8, 2024

Study completion Oct 8, 2024

Sponsor

Lead sponsor
TransgeneIndustry
Sponsor type
Industry
First posted
Feb 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, open-label, single arm phase I study evaluating the safety and tolerability as well as some activity parameters of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma.

Conditions

  • Ovarian Carcinoma
  • Fallopian Tube Cancer
  • Peritoneal Carcinoma

Interventions

  • TG4050Drug

    Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability (Adverse Event Reported Per CTCAE v5)Time frame: Up to 1 year . Adverse events were collected from treatment initiation weekly for the first six weeks, every three weeks thereafter until 30 days after the last treatment administration.

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Phoenix

    Phoenix, Arizona

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • Mayo Clinic Rochester

    Rochester, Minnesota

  • Institut Curie

    Paris, France

  • Hôpital Pitié-Salpêtrière

    Paris, France

  • IUCT Toulouse

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.